Nordic Life Science Days and ECCP2014 merge

/in , /by

occ-strek

Oslo Cancer Cluster and French partner Cancer-Bio-Santé are joining forces with SwedenBio to offer the global Life Science industry the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering.

Already now oncology biotechs, early stage companies and academics may submit an application for presenting at NLSDays-ECCP 2014 – see more info here.

The 6th European Cancer Cluster Partnering (ECCP) will be integrated in the Nordic Life Science Days in Stockholm September 7. – 9, 2014 as a special Oncology track. Cancer clusters from different European countries have already indicated their interest to team-up for the combined ECCP Oncology stream and the joint event.

“This collaboration is an excellent opportunity to further strengthen the European Cancer Cluster Partnering Platform we have built together with our partner Cancer-Bio-Santé since 2009. The joint event offers enhanced partnering opportunities with more than 800 international delegates and allows us to bring ECCP to Scandinavia once again”, says Oslo Cancer Cluster’s international advisor Jutta Heix.

Olivier Duchamp, Managing Director for Nordic Life Science Days is extremely pleased with the success of last years’ event and says: “This year, our aim is to enhance the Nordic region furthermore and be very focused on recent trends and success stories. We obviously contribute an add-on value to the international partnering arena.”

The 2014 website is launched, and delegates are welcome to register at www.nlsdays.com. Download the press release from the web launch here (pdf).

About Nordic Life Science Days (NLSDays)
Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech, but also from finances, research, policy and regulatory authorities. It is the largest Nordic partnering conference for the global Life Science industry, bringing together the best talents in Life Science, offering the excellent networking and partnering opportunities, providing inputs and content on the most recent trends.

About European Cancer Cluster Partnering (ECCP)
Since 2009, ECCP – the European Cancer Cluster Partnering has been established as an annual partnering arena for the international oncology community. ECCP offers a vital networking arena and is the direct result of the close collaboration between two of Europe’s strongest cancer clusters, the French Cancer-Bio Santé Cluster and the Norwegian Oslo Cancer Cluster. The key goal of ECCP is building partnerships to accelerate innovation in cancer treatment.

5 Oslo Cancer Cluster SMEs granted BIA-funding

/in , /by

Per Walday, CEO, PCI Biotech

Oslo Cancer Cluster Category

The Norwegian Research Council recently granted BerGenBio, PCI Biotech, Lytix Biopharma, Oncoinvent and Ultimovacs –  all Oslo Cancer Cluster member companies – funding  through the Programme for User-Driven Research Based Innovation (BIA).

In total, the Research Council will grant a record amount of 444 million to 58 Norwegian companies over four years, of which 10 are biotech companies – which is also a new record.

BerGenBio, Lytix Biopharma, PCI Biotech, Oncoinvent and Ultimovacs will receive around 10 million NOK each over 4 years, depending on the outcome of the contract negotiations between the council and the company. Funding from the  BIA programme is a quality stamp since the companies compete in “open class” where all sectors are represented. The funding may also in turn trigger interest  from private investors.

On the Research Council`s website you may find the total list of all the 58 companies (in Norwegian) and read more about the funding from the BIA-programme.

5 Oslo Cancer Cluster SMEs granted BIA-funding

/in , /by

Per Walday, CEO, PCI Biotech

Oslo Cancer Cluster Category

The Norwegian Research Council recently granted BerGenBio, PCI Biotech, Lytix Biopharma, Oncoinvent and Ultimovacs –  all Oslo Cancer Cluster member companies – funding  through the Programme for User-Driven Research Based Innovation (BIA).

In total, the Research Council will grant a record amount of 444 million to 58 Norwegian companies over four years, of which 10 are biotech companies – which is also a new record.

BerGenBio, Lytix Biopharma, PCI Biotech, Oncoinvent and Ultimovacs will receive around 10 million NOK each over 4 years, depending on the outcome of the contract negotiations between the council and the company. Funding from the  BIA programme is a quality stamp since the companies compete in “open class” where all sectors are represented. The funding may also in turn trigger interest  from private investors.

On the Research Council`s website you may find the total list of all the 58 companies (in Norwegian) and read more about the funding from the BIA-programme.

Presentations from cancer nanomedicine seminar

/in , /by

Professor Kirsten Sandvig

occ-strek

Friday January 31 Oslo Cancer Cluster, SINTEF, NTNU, Oslo University Hospital and the Norwegian Cancer Society  invite Norwegian media and other interested parties to join a breakfast seminar on nano cancer medicine.

The seminar is held in conjunction with 12 similair events across the whole of Europe in relation to Nano World Cancer Day. Below you may find the program and presentations at the breakfast meeting.

On the picture above you may see professor Kirsten Sandvig and her group at the Insitiute of Cancer Research. Sandvig was one of the presenters at the press seminar, which was developed in close collaboration with two of her co-workers: Tore Skotland and Tore-Geir Iversen.

 

Pressefrokost om nanokreftmedisin

Tid: Fredag 31. januar 2014 kl 08:15 – 10:30
Sted: Kreftforeningen, Tullins gate 2,Oslo

Kreftforeningen, Oslo Cancer Cluster, Sintef, NTNU og Institutt for Kreftforskning ved Oslo universitetssykehus inviterer til pressefrokost om nanokreftmedisin 31. januar 2014.

Frokosten arrangeres som Norges bidrag inn i det europeiske initiativet ”Nano World Cancer Day 2014” – der 13 land arrangerer tilsvarende pressefrokoster over hele Europa samtidig.

Vi ønsker med dette å gi journalister en kort introduksjon til et spennende område innen moderne kreftbehandling, både fra forsknings og utviklingssiden: Hva skjer når vi kombinerer nanomedisin og kreftmedisin?

Program:
O8:15 – 08:30 – Kaffe og frokost

08:30 – 08:35 – Kreftforeningen innleder ved Generalsekretær Anne Lise Ryel

08:35 – 08:45 – “Hva er nanokreftmedisin?”
Markedsdirektør Ruth Schmid, SINTEF

08:45 – 08:55 – ”Cellegift mot kreft – ‘gammelt’ prinsipp med nye muligheter?”,
Kreftlege og forsker Olav Engebråten, Oslo Universitetssykehus, Avdeling for kreftbehandling.

08:55 – 09:05 – ”Nanopartikler til bruk i kreftbehandling og diagnostikk”
Professor Kirsten Sandvig, Institutt for kreftforskning

09:05 – 09:15: ”Ultralyd forbedrer levering av nanopartikler til kreftsvulster”
Professor Catharina Davies, NTNU

09:15 – 09: 25: ”Lysdirigert levering av nanomedisiner”
Forskningssjef Anders Høgset, PCI Biotech

09:25 – 09:30: Oppsummering fra Forskningsrådet
Avdelingsdirektør Vidar Skagestad

Moderator: Elisabeth Kirkeng Andersen, kommunikasjonssjef Oslo Cancer Cluster

Links:
www.nanoworldcancerday.eu
www.etp-nanomedicine.eu/public